By asianet
PANDORUM International Inc. has engaged EVOLUTION Life Science Partners to assist the company in raising capital to fund the ongoing development of its assets, primarily Bioengineered Liquid Cornea, advanced therapeutics to promote cornea regeneration. The capital would support the clinical translation of the first in class, first in human tissue regenerative reprogramming treatment via Phase … Continued
By asianet
— Company achieves Top Performer status in ISR IRT Benchmark Survey Suvoda LLC ( https://c212.net/c/link/?t=0&l=en&o=3756407-1&h=3282413622&u=https%3A%2F%2Fwww.suvoda.com%2F%3Futm_medium%3Dpress-release%26utm_source%3Dpress-release%26utm_campaign%3Dmomentum-release-2023%26utm_content%3Dpress-release-momentum-2023-01&a=Suvoda+LLC ) , a global clinical trial technology company that specializes in complex studies in therapeutic areas like oncology, central nervous system (CNS), and rare disease, surpassed 1,000 clinical trials in 2022 as study deployments surged nearly 20%, a strong indicator … Continued
By asianet
– Designed and validated to handle high potent molecules less than 1 microgram/m3 containment – First commercial production batch has commenced Sai Life Sciences, one of India’s fastest growing Contract Research [ https://www.sailife.com/?utm_source=pr&utm_medium=web&utm_campaign=hpapi-bidar ] , Development & Manufacturing Organizations [ https://www.sailife.com/?utm_source=pr&utm_medium=web&utm_campaign=hpapi-bidar ] (CRO-CDMO), today announced the opening of a new High-Potency API (HPAPI) manufacturing facility … Continued
By asianet
– Enforcing Company’s R&D Efforts for New Lens Care Products and Global Professional Relation Activities – OPHTECS Corporation (hereinafter referred to as OPHTECS), a Kobe-based company which researches, develops, produces and markets contact lens care products, has signed a new advisory contract with Dr. Cristina M. Schnider as the company’s Senior Director, Global Medical Affairs. … Continued
By asianet
Esaote, a leading company in the biomedical sector – in ultrasound, dedicated magnetic resonance imaging and Information Technology for healthcare – is Supporter of “The Ocean Race: Genova, the Grand Finale”. As such, it will be taking part in the Round the World sailing race and will be protagonist in the arrival stage, June 24th … Continued
By asianet
Taking the trophy as the one of the best products in Taiwan at Taiwan Excellence Awards 2023, TPIsoftware’s SysTalk.Chat(https://www.tpisoftware.com/en/products/systalk-chat), the conversational AI chatbot, has reached new heights in driving smart healthcare with AI-powered customer services. By adopting SysTalk.Chat, Chang Gung Memorial Hospital (CGMH), the largest hospital in Taiwan, has become the first medical institution in … Continued
By asianet
– Acromegaly and gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare diseases that require life-long chronic treatment. Monthly somatostatin analog (SSA) injections are the standard of care as first-line medical treatment. – Debiopharm is developing Debio 4126, a novel 3-month extended-release octreotide formulation, to optimize acromegaly and GEP-NET patient care by reducing injection frequency, which translates into … Continued
By asianet
– The genome database will power ongoing scientific efforts worldwide and help advance individualized pet health care – Insights from this partnership will feed into the MARS PETCARE BIOBANK(TM), a longitudinal study to understand pet health and disease, transforming pet care for future generations of dogs and cats – Mars Petcare Science & Diagnostics President, … Continued
By asianet
SELUTION SLR(TM), MedAlliance’s novel sirolimus-eluting balloon, has received conditional FDA Investigational Device Exemption (IDE) approval to initiate its pivotal clinical trial for the treatment of coronary de novo lesions. This comes less than eight months after the company received its first IDE approval for SELUTION SLR in the treatment of below-the-knee (BTK) indications; as well … Continued
By asianet
Ajinomoto Co., Inc. (“Ajinomoto Co.”) today announced a license agreement with Exelixis, Inc. (“Exelixis”) to incorporate AJICAP(R), Ajinomoto Co.’s proprietary site-specific bioconjugation and linker technologies, in the development of certain of Exelixis’ antibody-drug conjugate (ADC) programs. Logo – https://mma.prnewswire.com/media/751177/Aji_BioPharma_Logo.jpg Exelixis is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and … Continued